New Insights
Into Genital Pain in Women - 1/29/2008
NY Times
When a woman complains of genital pain so severe that it makes
sexual intercourse all but impossible, her partner may jump to
the conclusion that she has a phobia about sex. But what if that
same woman also experiences excruciating pain when trying to insert
a tampon, undergo a pelvic exam, wear a pair of jeans, ride a bicycle
or go jogging? Can phobia explain all those problems?
Not very likely. In fact, studies have shown that sexual phobias
are rarely the explanation for a condition known as vulvodynia,
a chronic discomfort of the vulva that can result in searing or
shooting pain when any amount of pressure is placed on the sensitized
tissues. Some women compare the feeling to acid being poured on
an open wound.
The problem can last months, years or a lifetime. Worse, doctors
often misdiagnose it or treat it inappropriately, if at all.
For decades, women suffering from vulvodynia
have been told that nothing seems to be wrong with them — nothing, that is, that
the examining physician can discern — or that the condition
may be real but that nothing can be done.
Christin Veasley of Providence, R.I., said that vulvodynia, which
was diagnosed at age 18 during her freshman year at college, made
it impossible for her to sit long enough to finish a midterm exam.
Her doctor said there was no help for her condition.
The typical patient sees as many as a half-dozen doctors before
finding one who acknowledges she has a real medical problem, even
as the condition is yielding increasingly to an understanding of
its causes and the development of more effective treatments.
To help counter the prevailing therapeutic nihilism, in 2006 the
American College of Obstetricians and Gynecologists and the American
Academy of Family Physicians sent information to 150,000 of their
members, alerting them to the proper diagnosis of vulvodynia and
the best ways to treat it.
A recent study financed by the National Institutes of Health and
conducted by Bernard Harlow at Harvard University indicated that
as many as one woman in six, or 13 million American women, may
suffer from vulvodynia during their lives. As with Ms. Veasley,
for 6 percent of women the symptoms begin before age 25 and are
usually limited to burning pain in response to touch or pressure
at the opening of the vagina.
A second type of vulvodynia is more generalized.
Phyllis Mate of Potomac, Md., executive director of the National
Vulvodynia Association (www.nva.org), said in an interview that
her symptoms, which had been mild for 15 years, “exploded” at
age 40.
“I was incapacitated, afraid to walk and confined to bed
on narcotic painkillers,” Ms. Mate said. Nothing else helped,
not antidepressants or topical anesthetics, and a biopsy — no
longer done for this condition — revealed no treatable infection,
only nonspecific inflammation.
New Findings
Dr. William Ledger, professor emeritus of
obstetrics and gynecology at the Weill Medical College of Cornell
University and an expert on vulvodynia, said, “It is clear that there are subdivisions
of this condition — one diagnosis doesn’t fit everyone.”
Working with Steven S. Witkin, Dr. Ledger
has found two genetically based predisposing factors. In one,
the women produce inadequate amounts of a substance that blocks
an inflammatory response. “They
get an inflammatory response to an infection,” Dr. Ledger
said, “but it doesn’t go away.”
Another genetic aberration results in unstable production of a
substance that normally responds to an invasion by yeast or bacteria,
placing them at increased risk of chronic infections.
Using a dermatological instrument that reveals
two cell layers beneath the skin, Dr. Ledger said, “we’re seeing much
more widespread inflammation in these patients than appears to
the naked eye.” He added that he had treated patients who
had vulvar inflammation with local estrogen or steroids; while
they looked 80 percent better on the surface, their symptoms were
only about 20 percent better, because the inflammation remained
beneath the surface.
In addition, Dr. Ledger said, “there’s good evidence
that with vulvodynia as a whole, the women have more nerve fibers
in the vulva and they are firing more pain signals to the brain.” He
continued: “It’s a kind of vulvar fibromyalgia. Most
patients with vulvodynia have very tender glands at the entrance
to the vagina.”
In fact, several recent studies have shown up to a tenfold increase
in the density of nerve endings in what is called the vulvar vestibule.
In some cases the women appear to have been born with this overabundance
of nerve endings. But as Dr. Andrew T. Goldstein, a gynecologist
at Johns Hopkins School of Medicine, and colleagues reported in
2006 in The Journal of Sexual Medicine, excessive nerve endings
may also be caused by nerve growth factors after an inflammatory
response or from hormonal changes like those induced by oral contraceptives.
Helpful Treatments
Ms. Veasley, now a 32-year-old wife and
mother of two, spent seven years trying “a laundry list of treatments,” which,
she said, “only provided minimal relief” for her condition,
called vulvar vestibulitis. Shortly after marrying, she decided
to try surgery to remove the layer of tissue containing an overabundance
of nerve endings. She and her husband were finally able to have
intercourse, and a year later their first daughter was born. Ms.
Veasley said she had been “virtually pain-free” ever
since.
But as successful as her final treatment was, Ms. Veasley, who
serves as associate executive director of the vulvodynia association,
also knows that surgery is not an option for everyone. As Dr. Goldstein
reported, it is most successful in women whose pain is limited
to the vulvar vestibule and those without extreme muscle dysfunction
of the lower pelvis. Surgery is also more effective if done sooner,
rather than later, after the development of life-inhibiting symptoms.
Ms. Mate’s symptoms responded to another approach — two
treatments to inhibit firing of the pudendal nerve, which enervates
the lowest muscles of the pelvis, plus regular use of an anticonvulsant
drug. The combination, she said, “enables me to lead a reasonably
normal life,” though both pressure and heat, as occur with
prolonged sitting or wearing fitted pants, make her symptoms worse.
Dr. Ledger said patients with low production of inflammatory blockers
are often helped by Cox-2 inhibitor drugs like Celebrex (though
Vioxx, which is no longer marketed, worked better). Others find
relief with drugs used off-label, like low-dose hydroxyzone or
gabapentin to reduce nerve impulses from the vulva to the brain,
mood elevators in low doses and the muscle relaxant Flexeril.
The National Institutes of Health recently began a vulvodynia
awareness campaign at orwh.od.nih.gov/health/vulvodynia.html,
which offers resources and information. Also free is a professional
paper, “The
Vulvodynia Guideline,” by Dr. Hope K. Haefner of the University
of Michigan and 13 other experts. It is available in The Journal
of Lower Genital Tract Disease, www.jlgtd.com, under the archives
tab, on Page 40 of the January 2005 issue.